Medicortex continues research with the US Department of Defense
22.5.2026 11:15:51 EEST | Medicortex Finland Oyj | Press release
Medicortex Finland Plc, a biotechnology company based in Turku, Finland, announces continued development of saliva test for early detection of Traumatic Brain Injury (TBI) in the ongoing program with the U.S. Army Medical Research and Development Command (USAMRDC).
The granted extension will continue the project which commenced in 2024 by one year, with the extended project period now running through June 2027. The continuation enables further development of the saliva based TBI test and strengthening its performance for rapid and accurate detection of TBI in decentralized field-testing conditions. The total funding for this project, awarded by the Department of Defense (DoD) in June 2024, amounts to approximately USD 1.4 million and covers the full project period from June 2024 through June 2027. No additional funding has been awarded in connection with this extension.
“This is great news and I see it underlining the DoD’s confidence in Medicortex’s capacity to develop innovative solutions to tackle medical issues frequently encountered in the military activity”, says Dr. Adrian Harel, the CEO and founder of Medicortex. “Together with the forthcoming corporate arrangement this will allow us to continue our activity to translate research results into clinical utility on a stronger base”, Dr. Harel concludes.
The structural arrangement mentioned by the CEO refers to the intended business transaction between the Swedish company Nosium AB (publ) and Medicortex whereby Nosium is acquiring the majority of shares in Medicortex from company’s shareholders via a share swap. After completion of the planned transaction the shares will be publicly traded at Nordic Growth Market NGM in Stockholm and the company will get better access to the international financial markets.
Forward-looking statements
Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the expectations conveyed in these statements. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.
Keywords
Contacts
Adrian Harel, CEO
Tel: +358 400 488 817
Email: adrian.harel@medicortex.fi
Links
About the company
Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an experienced Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.
Subscribe to releases from Medicortex Finland Oyj
Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oyj
Medicortex Finland Oyj Welcomes NGM’s Conditional Approval for Continued Listing of the Combined Group22.6.2026 08:31:59 EEST | Press release
Medicortex Finland Oyj (“Medicortex Finland”) today comments on the announcement that Nordic Growth Market NGM AB (“NGM”) has granted conditional approval for NOSIUM AB (publ) — which is in the process of changing its name to Medicortex International AB (publ) — to continue trading on NGM Growth Market following completion of its reverse takeover of Medicortex Finland.
Medicortex now trademarked12.6.2026 08:20:00 EEST | Press release
The Finnish biotechnology company Medicortex Finland Plc announces approval of the trademark MedicortexTM by the European Union Intellectual Property Office (EUIPO).
A European patent granted for Medicortex11.12.2025 17:00:00 EET | Press release
The European Patent Office (EPO) has granted a patent for Medicortex Finland Oyj, a biopharmaceutical company focusing on development of diagnostics and treatments for traumatic brain injury (TBI). The patent strengthens Medicortex's unique approach for detection of glycan-based indicators of brain trauma.
Medicortex Signs a Share Purchase Agreement (SPA) with Nosium Ab (publ) – Strengthens Path Toward Commercializing TBI Diagnostics24.11.2025 10:13:02 EET | Press release
Medicortex Finland Oyj (“Medicortex”), together with its majority shareholders, has signed a binding SPA with Nosium Ab (publ) (“Nosium”), marking a significant step toward advancing the commercialization of Medicortex’s rapid diagnostic tests for traumatic brain injury (TBI). Under the agreement, Nosium intends to acquire up to 89.9 percent of Medicortex at a valuation of EUR 1 per share. The agreement underscores strong confidence in Medicortex’s biomarker-based, non-invasive diagnostic approach for TBI.
A patent granted for Medicortex28.8.2025 12:00:00 EEST | Press release
Medicortex Finland Plc, a biopharmaceutical company focusing on development of diagnostics and drugs for mild traumatic brain injury (TBI), was granted a patent in Israel for company’s innovative method and device for non-invasive detection of TBI.